YU201288A - Process for preparing tetrahydro-pyridins - Google Patents

Process for preparing tetrahydro-pyridins

Info

Publication number
YU201288A
YU201288A YU02012/88A YU201288A YU201288A YU 201288 A YU201288 A YU 201288A YU 02012/88 A YU02012/88 A YU 02012/88A YU 201288 A YU201288 A YU 201288A YU 201288 A YU201288 A YU 201288A
Authority
YU
Yugoslavia
Prior art keywords
pyridins
preparing tetrahydro
tetrahydro
preparing
Prior art date
Application number
YU02012/88A
Other languages
English (en)
Inventor
A Harreus
K H Weber
G Walther
W Stransky
F J Kuhn
G Schingnitz
H Ensinger
Original Assignee
Boehringer Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Kg filed Critical Boehringer Kg
Publication of YU201288A publication Critical patent/YU201288A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU02012/88A 1987-10-29 1988-10-27 Process for preparing tetrahydro-pyridins YU201288A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873736664 DE3736664A1 (de) 1987-10-29 1987-10-29 Tetrahydro-furo- und -thieno(2,3-c)pyridine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
YU201288A true YU201288A (en) 1990-08-31

Family

ID=6339349

Family Applications (1)

Application Number Title Priority Date Filing Date
YU02012/88A YU201288A (en) 1987-10-29 1988-10-27 Process for preparing tetrahydro-pyridins

Country Status (17)

Country Link
EP (1) EP0314154A3 (cs)
JP (1) JPH01157983A (cs)
KR (1) KR890006650A (cs)
AU (1) AU2443588A (cs)
CS (1) CS273193B2 (cs)
DD (1) DD283395A5 (cs)
DE (1) DE3736664A1 (cs)
DK (1) DK603588A (cs)
FI (1) FI884947A7 (cs)
HU (1) HU201553B (cs)
IL (1) IL88184A0 (cs)
NO (1) NO884835L (cs)
PL (1) PL275555A1 (cs)
PT (1) PT88899B (cs)
SU (1) SU1657064A3 (cs)
YU (1) YU201288A (cs)
ZA (1) ZA888089B (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5272148A (en) * 1992-09-09 1993-12-21 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarenylpiperazines
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
PL208386B1 (pl) * 2000-07-06 2011-04-29 Daiichi Sankyo Company Sole addycyjne 2-acetoksy-5-(α-cyklopropylokarbonylo-2-flurobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, lekarstwo zawierające jako składnik czynny te sole, zastosowanie soli, sposoby wytwarzania soli addycyjnych 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, sposób wytwarzania chlorowodorku 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny
AU2003217747A1 (en) * 2002-02-26 2003-09-09 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
EP1734941A2 (en) 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CN101675058A (zh) * 2007-03-02 2010-03-17 第一三共株式会社 用于制备高纯度普拉格雷盐酸盐的方法
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4090424A4 (en) 2020-01-13 2024-02-21 The Feinstein Institutes for Medical Research TREATMENT OF BLEEDING AND BLEEDING DISORDERS BY HIGH-INTENSITY FOCUSED ULTRASONIC STIMULATION OF THE SPLEEN
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
EP4466064A4 (en) 2022-01-20 2026-01-14 Setpoint Medical Corp TREATMENT OF INFLAMMATORY DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (fr) * 1975-06-27 1977-01-21 Parcor Nouveaux derives de la thieno (2,3-c) pyridine, leur preparation et leurs applications
FR2317303A1 (fr) * 1975-07-09 1977-02-04 Parcor Procede de preparation de derives de la tetrahydrothieno (3,2-c) et (2,3-c) pyridine

Also Published As

Publication number Publication date
EP0314154A3 (de) 1990-12-05
JPH01157983A (ja) 1989-06-21
EP0314154A2 (de) 1989-05-03
DE3736664A1 (de) 1989-05-11
IL88184A0 (en) 1989-06-30
KR890006650A (ko) 1989-06-15
NO884835D0 (no) 1988-10-28
NO884835L (no) 1989-05-02
DK603588D0 (da) 1988-10-28
CS273193B2 (en) 1991-03-12
FI884947L (fi) 1989-04-30
FI884947A7 (fi) 1989-04-30
DD283395A5 (de) 1990-10-10
HU201553B (en) 1990-11-28
FI884947A0 (fi) 1988-10-27
HUT50824A (en) 1990-03-28
SU1657064A3 (ru) 1991-06-15
DK603588A (da) 1989-04-30
PT88899B (pt) 1993-01-29
AU2443588A (en) 1989-07-13
ZA888089B (en) 1990-07-25
CS712688A2 (en) 1990-06-13
PL275555A1 (en) 1989-05-02

Similar Documents

Publication Publication Date Title
EG18230A (en) Process for preparing 3-aryloxy-3-substituted propanamines
YU34587A (en) Process for preparing purinic nucleozides
YU157188A (en) Process for obtaining 5-heterocyclical-substituted oxazolidinic dihaloacetats
ZA876516B (en) Process for preparing 3-pyrrolidinols
EP0245960A3 (en) Process for preparing n-acyltetrahydroisoquinoline
YU24088A (en) Process for preparing heterocyclical compounds
YU192288A (en) Process for preparing quinolynic derivatives
EP0283905A3 (en) Process for preparing chloropolysilanes
YU234688A (en) Process for obtaining acylderivative
YU112188A (en) Process for preparing 2-metoximethylpenem derivatives
YU119887A (en) Process for preparing dihydroizoquinolines
YU159688A (en) Process for preparing anilynphenyl-thiourins, -izothiourins and -carbonimides
GB8810248D0 (en) Process for obtaining scualane
YU159788A (en) Process for preparing phenyl-thiourins, -izothiourins and -carbonimides
YU45062B (en) Process for obtaining anilynofumarate
CS331887A2 (en) Process for preparing tetrahydrotetramethylnaphthylpropenylphenoles
YU142288A (en) Process for preparing tetrahydro-benzothiazolo-quinolines
CS254287A1 (en) Process for preparing alkoxyphenoles
CS93387A1 (en) Process for preparing o-chlorbenzamide
GB2202850B (en) Process for preparing ketocholanate
PT86534A (en) Process for preparing 2-heterocyclylalkyl-2-penem compounds
ZA879589B (en) Process for preparing alkoxyalkylidenehydrazinopyridazine derivatives
HUT43041A (en) Process for preparing tetrachloro-pyridine
CS894587A1 (en) Process for preparing 4-amino-1-phenyl-5-chlor-6-oxo-1h-pyridazine
GB8723614D0 (en) Process for preparing 1-hydroxypyrrolizidin-3-ones